Nimbus hopes to best Bristol’s Sotyktu
Nimbus aims to push Tyk2 inhibition to the limit with its more selective project, but others have a similar idea.
Galapagos starts spending Gilead’s cash
A surprise move into the Car-T space suggests the beleaguered Belgian biotech still has an eye on its rich benefactor.
The lung fibrosis pipeline thins
This month Pliant Therapeutics claimed a win in idiopathic pulmonary fibrosis, but other projects have fallen by the wayside.
Roxadustat shows the latest regulatory fault line split
Fibrogen’s controversial anaemia pill becomes the latest example of markedly different regulatory stances taken in Europe and the US.
No hiding the Toledo disappointment for Galapagos
GLPG3970 is biologically inert in ulcerative colitis and rheumatoid arthritis, so Galapagos’s search for something better goes on.
Go or no go? Ardelyx and Chemocentryx among those waiting FDA decisions
Big regulatory events for July include a panel for Fibrogen's roxadustat and decision time for Albireo; elsewhere, Jak inhibitor delays could persist.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
